Stock data
| Market cap. | €107.1m |
| Last close | €2.45 |
| High / Low (52 weeks) | €8.8 / €2.2 |
| Stock market listing | Euronext Brussels |
| Forecast net cash (€m) | 54.7 |
| Forecast gearing ratio (%) | N/A |
| Team | Healthcare |
| Sector | Pharmaceutical & Healthcare |
Price performance
| % | 1m | 3m | 12m |
|---|---|---|---|
| Actual | (23.676) | (19.6721) | (69.2211) |
| Relative * | (18.7587) | (13.7756) | (60.0925) |
* % Relative to local index
Other companies covered in sector
| Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2010A | 31.4 | (23.0) | (24.0) | (56.9) | N/A | N/A |
| 2011A | 21.9 | (42.8) | (43.3) | (99.1) | N/A | N/A |
| 2012E | 26.2 | (36.9) | (39.1) | (89.6) | N/A | N/A |
| 2013E | 36.7 | (28.1) | (30.8) | (70.4) | N/A | N/A |
Last updated on 19/04/2012
Latest research
A look beyond ‘103
Update | Pharmaceutical & Healthcare | 14/03/2012
The refined strategy
Review | Pharmaceutical & Healthcare | 23/01/2012
Progress on many fronts
Update | Pharmaceutical & Healthcare | 07/12/2011
Pfizer returns TNF rights
Update | Pharmaceutical & Healthcare | 08/11/2011
Promising H2 in prospect
Update | Pharmaceutical & Healthcare | 26/08/2011
Positive Phase II data
Update | Pharmaceutical & Healthcare | 19/05/2011
Pfizer’s data and decision
Review | Pharmaceutical & Healthcare | 25/02/2011
More of the same
Update | Pharmaceutical & Healthcare | 19/11/2010
Not the average biotech
Review | Pharmaceutical & Healthcare | 02/11/2010
Collaboration extended
Update | Pharmaceutical & Healthcare | 12/10/2010
Continued progress
Update | Pharmaceutical & Healthcare | 05/10/2010
Size does matter
Outlook | Pharmaceutical & Healthcare | 16/09/2010
Investment summary
Ablynx has developed a broad pipeline using its Nanobody technology in many disease areas. These novel therapeutic proteins have the specificity of monoclonal antibodies and many of the benefits of small molecules. Its lead Nanobody, ozoralizumab (ATN-103 for the $21bn TNF market), successfully completed a Phase II study in rheumatoid arthritis (RA) and Ablynx is looking for a new partner (Pfizer previously had the rights to the product). Ablynx has two other Nanobodies in Phase II trials, ALX-0081/0681 in TTP and ALX-0061 in RA. Ablynx is increasing its business development activities, which should be helped by Novartis's decision to advance its Nanobody into Phase I. It is also more flexible about the terms of potential partnerships and when it will partner programmes. It should have enough cash to operate beyond 2014.
Last updated on 23/04/2012
Industry outlook
There is a strong demand for novel pharmaceutical products. The characteristics of Ablynx's Nanobodies and the initial results from clinical trials mean they have considerable commercial potential in many indications.
Last updated on 23/04/2012
Key management
| Edwin Moses, Chairman & CEO |
| Wim Ottevaere , FD |
Company address
| Technologiepark 4 9052 Ghent/Zwijnaarde Belgium +32 (0)9 262 00 00 View website |
